IRIS Macrotipologia:https://hdl.handle.net/10807/12026-08-27T03:27:08Z2026-08-27T03:27:08ZAssociation between canakinumab dose and long-term remission in Still's disease: insights from the AIDA network registryhttps://hdl.handle.net/10807/3451512026-08-27T00:18:23Z2026-01-01T00:00:00ZTitolo: Association between canakinumab dose and long-term remission in Still's disease: insights from the AIDA network registry
Autori: Vitale A; Caggiano V; Sbalchiero J; Lopalco G; Tufan A; Ragab G; Sfikakis PP; Dagna L; Batu ED; Ozen S; Conti F; Maiolini F; Bugatti S; Frassi M; Ruscitti P; Morrone M; La Torre F; Cakir IY; Akay N; Kilic Konte E; Laskari K; Bilginer Y; Gattamelata A; Croce J; De Stefano L; Voltarel G; Cipriani P; Maggio MC; Al-Mayouf SM; Fotis L; Rigante D; Sota J; Verrecchia E; Guggino G; La Barbera L; Piga M; Emmi G; Gallizzi R; Conti G; Sfriso P; Bartoloni E; Giacomelli R; Barone P; Olivieri AN; Alemanno A; Lo Gullo A; Direskeneli H; Alibaz-Oner F; Karamanakos A; Prete M; Edrees A; Gavioli F; Parronchi P; Ciccia F; Cardamone C; Hernández-Rodríguez J; Hatemi G; Bes C; Almaghlouth IA; Marhuenda ÁR; Gonzáles-García A; Gaggiano C; De Paulis A; Tezcan ME; Brucato AL; Feist E; Tornero-Romero F; Suzon B; Ogunjimi B; Thabet M; Conforti A; Pucino V; Boyarchuk O; Kovalchuk T; Govoni M; Iagnocco A; Chimenti MS; Moshrif A; Del Giudice E; Carubbi F; Erten Ş; Tharwat S; Hegazy MT; Więsik-Szewczyk E; Torres-Ruiz J; Martín-Nares E; Balistreri A; Fabiani C; Frediani B; Hinojosa-Azaola A; Kasapçopur Ö; Cantarini L
Abstract: Objective: The primary aim of this study was to assess, in Still’s disease, whether the employment of canakinumab at a strictly on-label dose may increase the likelihood of treatment discontinuation due to study-defined long-term remission (LTR), compared with patients receiving lower doses. Methods: Patients were drawn from the international Autoinflammatory Disease Alliance (AIDA) Network registry dedicated to Still’s disease and stratified based on the starting canakinumab dose: the on-label group received either 300 mg every 4 weeks or 150 mg every 4 weeks (corresponding to 4 mg/kg), while the underdosed group received 150 mg every 4 weeks (corresponding to a dose not exceeding 3.5 mg/kg). Bayesian regression models were implemented to estimate the probability of achieving long-term remission with subsequent canakinumab withdrawal in the two groups, as well as the mean differences in probabilities and posterior probabilities indicating whether the on-label group was superior in achieving the endpoint. Results: In total, 131 patients (16.7%) were enrolled, 81 (61.8%) receiving the on- label posology and 50 (38.2%) the underdosed posology. The estimated marginal posterior probability of canakinumab discontinuation due to LTR was 19% (CrI 7.5%–34.6%) in the on-label group and 3.9% (CrI 0.7%–15.2%) in the underdosed group, yielding a mean difference of 15.1% (CrI 1.4%–31.4%) and a posterior probability of 98.4%. This difference remained credible, with posterior probabilities ranging from 97.9% to 99.6%, irrespective of disease course or age at disease onset. Conclusion: On-label canakinumab dosing appears to increase the likelihood of study-defined LTR with subsequent treatment discontinuation, compared with underdosed treatment strategies.2026-01-01T00:00:00ZIdiopathic Raynaud’s phenomenon and vitamin D deficiency in children and adolescents: an exploratory single-center retrospective observational study throughout the period 2010-2025https://hdl.handle.net/10807/3451502026-08-27T00:18:28Z2026-01-01T00:00:00ZTitolo: Idiopathic Raynaud’s phenomenon and vitamin D deficiency in children and adolescents: an exploratory single-center retrospective observational study throughout the period 2010-2025
Autori: Rigante D; Fastiggi M; Guerriero C; Candelli M
Abstract: Background: Raynaud’s phenomenon (RP) may occur in the pediatric age span, sometimes representing the forerunner of devious underlying conditions. Objective: To investigate the prevalence of vitamin D deficiency in a single-center cohort of children and adolescents with idiopathic RP and evaluate changes in RP severity following cholecalciferol supplementation. Patients and Methods: Sixty-one children and adolescents with RP regularly followed at the pediatric rheumatology unit of our University between 2010 and 2025 were retrospectively evaluated. Clinical, laboratory, and nailfold videocapillaroscopy (NVC) findings were collected at baseline; patients were periodically examined for a mean investigation period of 3 ± 1.6 years. RP severity was assessed using the 2-week Raynaud’s Condition Score (RCS). Patients found to have serum 25-hydroxyvitamin D levels < 20 ng/mL received cholecalciferol supplementation for at least 12 weeks. Results: Nineteen out of 61 patients with RP (31.1% of the cohort) had vitamin D deficiency, while other laboratory parameters including inflammatory markers, complement fractions, liver and renal function tests, lipid profile, and autoimmune panel were non-informative. Uni variate analysis demonstrated significant differences between vitamin D-deficient and non-deficient patients in terms of mean RP duration (p = 0.0002), baseline 2-week RCS (p = 0.0001), lupus-like anticoagulant positivity (p < 0.001), NVC pattern (p < 0.001), pain visual analogue scale (VAS) (p = 0.0001), and global quality of life VAS (p = 0.0001). After adjustment for age and sex, baseline 2-week RCS remained significantly associated with vitamin D deficiency. In addition, RCS significantly decreased during follow-up among vitamin D-deficient patients who received supplementation of cholecalciferol. Conclusions: Vitamin D deficiency may be common in pediatric idiopathic RP and pinpoint its severity: our exploratory study supports the routine assessment of vitamin D in children and adolescents with severe forms of RP, warranting prospective randomized controlled trials to determine whether correction of vitamin D deficiency may potentially improve disease severity.2026-01-01T00:00:00ZEffectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Networkhttps://hdl.handle.net/10807/3451492026-08-27T00:28:35Z2026-01-01T00:00:00ZTitolo: Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network
Autori: Vitale A.; Caggiano V.; Sbalchiero J.; Tufan A.; Ragab G.; Lopalco G.; Portincasa P.; Rigante D.; Al-Mayouf S. M.; Şahin A.; Tekgöz N.; Verrecchia E.; Fotis L.; Barone P.; Sfikakis P. P.; Batu E. D.; Gaggiano C.; Ozen S.; Bes C.; Akay N.; Konte E. K.; Aslan E.; Torunoglu Z.; Karakaya B.; Yildirim D.; Kucuk H.; Noto A.; Khalil M.; Sicignano L. L.; Alsaleem A.; Alsonbul A.; Babayiğit A.; Semanur E.; Kourtesi K.; Papa S.; Laskari K.; Deniz R.; Alemanno A.; Maggio M. C.; Hernández-Rodríguez J.; Gomez-Caverzaschi V.; De Paulis A.; Mormile I.; Aragona E.; Bronte F.; Gallizzi R.; Insalaco A.; Olivieri A. N.; Bilgin E.; Erdik N.; Saad M. A.; Robles-Marhuenda Á.; Lo Gullo A.; Conforti A.; Tornero Romero F.; Ogunjimi B.; Sener S.; Frassi M.; Conti G.; Cauli A.; Govoni M.; Marzano A. V.; Moltrasio C.; Więsik-Szewczyk E.; Tharwat S.; Moshrif A.; Karamanakos A.; Elmas S.; Balistreri A.; Frediani B.; Fabiani C.; Kasapçopur Ö.; Cantarini L.2026-01-01T00:00:00ZReply from Authors re: Manfred P. Wirth and Michael Froehner. Radical Prostatectomy-Only Centers: The Future in Genitourinary Surgery? Eur Urol 2010;57:953-4https://hdl.handle.net/10807/3451482026-08-27T01:20:33Z2010-01-01T00:00:00ZTitolo: Reply from Authors re: Manfred P. Wirth and Michael Froehner. Radical Prostatectomy-Only Centers: The Future in Genitourinary Surgery? Eur Urol 2010;57:953-4
Autori: Coelho R. F.; Rocco B.; Patel V. R.
Abstract: N/A2010-01-01T00:00:00Z